Latest Conference Coverage


Post-AAN Perspectives: Recapping Major Areas of Growth in Neurology

Post-AAN Perspectives: Recapping Major Areas of Growth in Neurology

May 23rd 2024

A trio of clinicians from Cleveland Clinic provided perspectives on the advances in neurology seen at the 2024 AAN Annual Meeting, specifically focusing in on epilepsy, stroke, and multiple sclerosis.


NeuroVoices: Katherine Peters, PhD, on Vorasidenib’s Impact on Quality of Life, Neurocognition, and Seizures in the Treatment of Gliomas

NeuroVoices: Katherine Peters, PhD, on Vorasidenib’s Impact on Quality of Life, Neurocognition, and Seizures in the Treatment of Gliomas

May 22nd 2024

The neurologist and neuro-oncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided clarity on a new analysis of the INDIGO study highlighting treatment benefits of vorasidenib in patients with IDH mutant grade 2 gliomas.


Frederic Schaper, MD, PhD  (Credit: Harvard Catalyst)

Exploring the Association Between Brain Lesions and Takotsubo Syndrome

May 21st 2024

Frederic Schaper, MD, PhD, an instructor in neurology at Brigham and Women's Hospital, discussed the complex interplay between brain lesions and takotsubo syndrome, a heart condition caused by physical and emotional triggers.


Susan W. Broner, MD  (Credit: Weill Cornell Medicine)

Essentials for Treating Headache as a General Neurologist

May 19th 2024

Susan W. Broner, MD, the medical director of the Weill Cornell Medicine Headache Program, talked about the essentials of diagnosing and treating various headache disorders from a general neurology perspective.


Reviewing Ravulizumab’s Long-Term Profile as New NMOSD Treatment

Reviewing Ravulizumab’s Long-Term Profile as New NMOSD Treatment

May 18th 2024

Sean Pittock, MD, director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology detailed interim data from the open-label extension of the pivotal CHAMPION-NMOSD trial, the study that led to ravulizumab’s approval.


CMSC 2024: What to Expect From This Year's Annual Meeting

CMSC 2024: What to Expect From This Year's Annual Meeting

May 15th 2024

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.


NeuroVoices: Jessica Ailani, MD, on Implications of DELIVER Analysis With Eptinezumab for Migraine Prevention

NeuroVoices: Jessica Ailani, MD, on Implications of DELIVER Analysis With Eptinezumab for Migraine Prevention

May 15th 2024

The director of the MedStar Georgetown Headache Center talked about results from an analysis on the DELIVER study assessing response rates of eptinezumab in patients with migraine over an 18-month period.


Adding New Mechanistic Agents to SMA Treatment: the Phase 3 RESILIENT Study

Adding New Mechanistic Agents to SMA Treatment: the Phase 3 RESILIENT Study

May 13th 2024

Lindsey Lee Lair, MD, a neurologist and vice president of clinical development at Biohaven Pharmaceuticals, provided insight on an ongoing pivotal trial assessing the impacts of taldefgrobep alfa, a myostatin inhibitor, in patients with SMA.


Anton P. Porsteinsson, MD

Early Treatment Response and Safety Profile of AXS-05 in Phase 3 ACCORD Trial: Anton P. Porsteinsson, MD

May 10th 2024

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester discussed treatment response and safety findings from the phase 3 ACCORD study assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 6 minutes]


Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN

Navigating Challenges and Opportunities With AI Adoption in Neurological Practice: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN

May 8th 2024

The neurologist at Mass General Hospital discussed adopting AI technologies in neurology practice, emphasizing the importance of addressing equity concerns alongside technological advancements. [WATCH TIME: 5 minutes]


Tarun Singhal, MD, MBBS

Promising Nasal Administration Treatment for Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS

May 8th 2024

The director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital talked about nasal administration of foralumab that shows promise in treating patients with non-active secondary progressive MS. [WATCH TIME: 5 minutes]


NeuroVoices: Kayla Scippa, on Recognizing Unmet Need in Chronic Demyelinating Polyneuropathy

NeuroVoices: Kayla Scippa, on Recognizing Unmet Need in Chronic Demyelinating Polyneuropathy

May 8th 2024

The associate director, Patient Reported Outcomes, Johnson & Johnson, provided clarity on a poster presentation from AAN 2024 examining the most critical aspects to CIDP disease severity.


Jessica Ailani, MD

Understanding the Impact of Data Analysis on Preventive Migraine Treatment: Jessica Ailani, MD

May 7th 2024

The director of the MedStar Georgetown Headache Center discussed the importance of maintaining hope and providing understanding of patients' frustrations in their treatment journey for migraine. [WATCH TIME: 5 minutes]


Understanding the Therapeutic Potential of Nipocalimab: Katie Abouzahr, MD

Understanding the Therapeutic Potential of Nipocalimab: Katie Abouzahr, MD

May 6th 2024

The vice president, Autoantibody Portfolio and Maternal Fetal Immunology Disease Area Leader, Johnson & Johnson, provided perspective on the unique molecular structure of nipocalimab seen across nonclinical and clinical studies. [WATCH TIME: 3 minutes]


Jaime Imitol, MD

A Call to Action to Address Disparities in Multiple Sclerosis Care: Jaime Imitola, MD

May 6th 2024

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]


Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD

Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD

May 3rd 2024

The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology departments. [WATCH TIME: 4 minutes]


Understanding the Root Causes of Cognitive Decline in Disadvantaged Neighborhoods

Understanding the Root Causes of Cognitive Decline in Disadvantaged Neighborhoods

May 2nd 2024

Tanisha Hill-Jarrett, PhD, an assistant professor of neurology at the University of California, San Francisco Memory and Aging Center, discussed the change needed to improve cognitive decline rates in Black women in disadvantaged neighborhoods.


Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD

Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD

May 2nd 2024

The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]


Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN

Leveraging Artificial Intelligence to Redefine Clinical Efficacy and Empower Neurologists: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN

May 1st 2024

The neurologist at Mass General Hospital talked about leveraging artificial intelligence to enhance clinical practice amidst growing demands and workforce shortages in neurology. [WATCH TIME: 4 minutes]


Anton P. Porsteinsson, MD

Latest Findings on AXS-05 Treatment for Agitation in Alzheimer Disease: Anton P. Porsteinsson, MD

May 1st 2024

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester talked about recent results on the phase 3 ACCORD trial assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 8 minutes]


Utilizing the SCACOMS Composite Measure to Assess Treatment Benefit of Troriluzole in Spinocerebellar Ataxia: Irfan Qureshi, MD

Utilizing the SCACOMS Composite Measure to Assess Treatment Benefit of Troriluzole in Spinocerebellar Ataxia: Irfan Qureshi, MD

April 30th 2024

The chief medical officer at Biohaven provided insight on its investigational spinocerebellar ataxia agent troriluzole, the advantages of the newly developed SCACOMS measure, and how the therapy stacks against natural history data. [WATCH TIME: 4 minutes]


Literature Review Demonstrates Ravulizumab’s Superior Efficacy Over Other Approved NMOSD Treatments

Literature Review Demonstrates Ravulizumab’s Superior Efficacy Over Other Approved NMOSD Treatments

April 29th 2024

In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relapse.


Complement Inhibitors Ravulizumab and Eculizumab Impact Measures of Neuroaxonal Damage

Complement Inhibitors Ravulizumab and Eculizumab Impact Measures of Neuroaxonal Damage

April 29th 2024

Ravulizumab reduced NfL levels in cerebrospinal fluid and serum whereas eculizumab showed no change in NfL when compared with placebo.


Tarun Singhal, MD, MBBS

Potential of Nasal Foralumab in Treating Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS

April 26th 2024

The associate professor of neurology at Harvard Medical School discussed findings from a study investigating nasal foralumab in patients with non-active secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]


Understanding the Cognitive Impact of Neighborhood Disadvantage on Black Women: Tanisha Hill-Jarrett, PhD

Understanding the Cognitive Impact of Neighborhood Disadvantage on Black Women: Tanisha Hill-Jarrett, PhD

April 26th 2024

The neuropsychologist and assistant professor of neurology at the University of California, San Francisco Memory and Aging Center provided comment on her presentation from AAN 2024 examining the association of area deprivation index with cognitive functioning in Black women. [WATCH TIME: 3 minutes]

© 2024 MJH Life Sciences

All rights reserved.